XVIVO Perfusion AB (publ) (“XVIVO”) has today completed the acquisition of all shares in the US organ recovery company Star Teams Inc. (“Star Teams”) that XVIVO announced on October 28, 2021.
Read moreXVIVO Perfusion AB (publ) (“XVIVO” or the “Company”) (Nasdaq Stockholm: XVIVO) has completed a directed share issue of 746,269 shares at a subscription price of SEK 335 per share (the “Directed Issue”), through which the Company receives approx. SEK 250 million before transaction costs.
Read moreXVIVO Perfusion AB (publ) (“XVIVO” eller “Bolaget”) (Nasdaq Stockholm: XVIVO) har genomfört en riktad nyemission av 746 269 aktier till en teckningskurs om 335 kronor per aktie (den ”Riktade Emissionen”), varigenom Bolaget tillförs cirka 250 miljoner kronor före transaktionskostnader.
Read moreXVIVO Perfusion AB (publ) (“XVIVO” eller “Bolaget”) (Nasdaq Stockholm: XVIVO) avser att genomföra en nyemission av aktier till ett belopp motsvarande cirka 250 miljoner kronor riktad till svenska och internationella institutionella investerare (den ”Riktade Emissionen”). XVIVO har anlitat Carnegie Investment Bank AB (publ) (”Carnegie”) och Bryan, Garnier & Co (”Bryan, Garnier & Co”) som Joint Bookrunners i samband med den Riktade Emissionen.
Read moreXVIVO Perfusion AB (publ) (“XVIVO” or the “Company”) (Nasdaq Stockholm: XVIVO) intends to carry out a new issue of shares with an amount of approximately SEK 250 million directed to Swedish and international institutional investors (the “Directed Issue”). XVIVO has appointed Carnegie Investment Bank AB (publ) (“Carnegie”) and Bryan, Garnier & Co (“Bryan, Garnier & Co”) to act as Joint Bookrunners in connection with the Directed Issue.
Read more
